Cegedim H1 2026 slides: margins expand as revenue growth stays modest

Cegedim reported H1 2026 revenue of €324.8 million, up only 0.7% year over year, but adjusted operating income rose 6.9% to €19.7 million and adjusted EBIT margin expanded 35bps to 6.1%. Operating free cash flow reached €58.9 million and net debt excluding IFRS 16 declined 17.3% to €150.4 million, supported by cost controls and lower one-off charges. Management maintained guidance for more than 2% like-for-like revenue growth and higher operating income in FY2026, although shares fell 2.55% as investors focused on weak top-line growth, a 16.4% decline in Cloud & Support revenue, and segment-level margin pressure.

Analysis

ALCGM’s investable issue is not the reported margin improvement but its durability: a meaningful portion of the earnings delta appears tied to lower exceptional charges, workforce reductions and working-capital release rather than demonstrated recurring top-line acceleration. With revenue concentrated in France and the stock relatively illiquid under controlling ownership, the market is likely to require evidence that regulatory-led demand converts into organic software growth before rerating the multiple. The October 22 Q3 release is the critical 1-3 month catalyst because it must validate the implied second-half acceleration embedded in maintained guidance.

Business Services can become the valuation anchor if e-invoicing creates high-retention, recurring software revenue rather than merely implementation activity; this would also pressure French payroll/ERP and document-workflow vendors serving smaller enterprises. Conversely, the loss-making healthcare-professional and cloud operations remain operating-leverage traps: another contract loss or delayed product adoption can consume the savings generated elsewhere. Rising capitalized development expenditure also deserves scrutiny—if amortization continues to outpace revenue growth, reported EBITDA may overstate economic free cash flow over the next 6-18 months.

The contrarian case is that the market is treating ALCGM as a no-growth French IT-services company while underpricing a potential mix shift toward regulated workflow software, payer fraud solutions and digital-health distribution. That thesis is premature absent proof in Q3: the company needs organic growth above 2%, stable or improving segment margins outside cost cuts, and no further deterioration in Cloud & Support. A failure on any of those metrics would likely renew multiple compression despite lower leverage.

Key Decisions for Investors

• Maintain a watch, not a directional position, into the October 22 Q3 revenue release; ALCGM’s low liquidity and concentrated ownership make a modest earnings surprise difficult to monetize without confirmed growth acceleration.
• Initiate a small long only if Q3 organic growth exceeds 2.5% and management reiterates improving recurring operating income without increasing capitalized R&D or restructuring needs. Target a 15-20% rerating over 6-12 months toward the upper half of the prior trading range; exit if organic growth remains below 1% or Cloud & Support losses widen.
• For existing holders, reduce exposure if net debt stops declining despite continued elevated investment spending. The key falsifier is cash conversion: operating cash flow must remain sufficient to fund development and infrastructure investment without renewed balance-sheet leverage.
• Monitor French e-invoicing implementation milestones and Ségur subsidy timing as near-term catalysts. Delays would disproportionately hurt the higher-margin Business Services and healthcare-software expectations that underpin the second-half guide.